PVCT PROVECTUS BIOPHARMACEUTICALS, INC.
Pharmaceutical Preparations · OTC · SEC CIK 315545 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-45.5%
TTM net income YoY-14.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-30.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,575.3%
Net margin-1,615.8%
FCF margin—
EBITDA margin-1,574.8%
Returns
ROE—
ROA-637.5%
ROIC (approx.)—
Asset turnover0.39x
Leverage & solvency
Liabilities / assets1,003.6%
Debt / equity—
Current ratio0.08x
Interest coverage-991.90x
Cash quality & payout
Operating cash flow / net income0.61x
Accruals ratio-247.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $336,108 | $617,140 |
| R&D expense | $1.90M | $2.05M |
| SG&A expense | $3.73M | $3.10M |
| Operating income | -$5.29M | -$4.53M |
| Interest expense | $5,338 | $13,591 |
| Pretax income | -$5.51M | -$4.77M |
| Net income | -$5.43M | -$4.73M |
| EBITDA | -$5.29M | -$4.53M |
| EPS (basic) | -0.01 | -0.01 |
| EPS (diluted) | -0.01 | -0.01 |
| Weighted avg. shares (diluted) | 420.28M | 419.81M |
| Banking | ||
| Net interest income | -$210,359 | -$239,073 |
| Balance sheet | ||
| Cash & equivalents | $251,291 | $307,442 |
| Current assets | $567,874 | $976,772 |
| PP&E, net | $3,000 | $4,863 |
| Total assets | $697,502 | $1.01M |
| Current liabilities | $6.90M | $6.98M |
| Total liabilities | $7.00M | $6.98M |
| Shareholders' equity | -$6.30M | -$5.96M |
| Shares outstanding | 420.28M | 420.28M |
| Cash flow statement | ||
| Operating cash flow | -$3.33M | -$3.28M |
| Financing cash flow | $3.09M | $2.75M |
| Depreciation & amortization | $1,863 | $7,157 |
| Stock-based compensation | $1.24M | $1.28M |
Free plan shows the latest 2 periods; Pro shows all 24 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.